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Diastolic timed Vibro-Percussion at 50 Hz
delivered across a chest wall sized meat barrier
enhances clot dissolution and remotely
administered Streptokinase effectiveness in an
in-vitro model of acute coronary thrombosis
Andrew Hoffmann1* and Harjit Gill2
Abstract
Background: Low Frequency Vibro-Percussion (LFVP) assists clearance of thrombi in catheter systems and when
applied to the heart and timed to diastole is known to enhance coronary flow. However LFVP on a clotted
coronary like vessel given engagement over a chest wall sized barrier (to resemble non-invasive heart attack
therapy) requires study.
Methods: One hour old clots (n=16) were dispensed within a flexible segment of Soft-Flo catheter (4 mm lumen),
weighted, interfaced with Heparinized Saline (HS), secured atop a curved dampening base, and photographed.
A ~4 cm meat slab was placed over the segment and randomized to receive intermittent LFVP (engaged, -
disengaged at 1 second intervals), or no LFVP for 20 minutes. HS was pulsed (~120/80 mmHg), with the diastolic
phase coordinated to match LFVP delivery. The segment was then re-photographed and aspirated of fluid to
determine post clot weight. The trial was then repeated with 0.5 mls of Streptokinase (15,000 IU/100 microlitre)
delivered ~ 2 cm upstream from the clot.
Results: LFVP - HS only samples (vs. controls) showed; a) development of clot length fluid channels absent in the control
group (p < 0.0002); b) enhanced dissolved clot mixing scores ( 5.0 vs. 0.8, p < 2.8 E – 6); and c) increased percent clot
dissolution (23.0% vs. 1.8% respectively, p < 8.5 E-6). LFVP - SK samples had a similar comparative clot disruptive profile,
however fluid channels developed faster and percent clot dissolution more than doubled (51.0% vs. 3.0%, p< 9.8 E- 6).
Conclusion: Diastolic timed LFVP (50 Hz) engaged across a chest wall sized barrier enhances clot disruptive effects to an
underlying coronary like system.
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Introduction
Thrombo-occlusive cardiovascular disease is the leading
cause of mortality in the developed world [1]. Among
these, acute ST-Elevation Myocardial Infarction (STEMI)
is an important disease with high morbidity and mortal-
ity, of which rapid and complete blood flow restoration
to the occluded artery is the main determinant of clinical
outcome [2]. Currently STEMI is preferably treated by
emergency Primary Percutaneous Coronary Intervention
(PPCI) where a balloon and a stent are deployed to open
the acutely thrombosed vessel. However significant in-
frastructure is required for PPCI and there are some-
times lengthy delays (often greater than 90 min) in
delivering a patient which leads to increased mortality
and morbidity [3]. Intravenous (IV) thrombolytic therapy
therefore remains a common alternative therapy world-
wide particularly in rural areas [4], however IV thromb-
olysis has a relatively low complete reperfusion rate and
has worrisome potential hemorrhagic complications [5].
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There is therefore an ongoing search for non-invasive
therapies with less serious side effects to enhance early
restoration of coronary flow.
Transthoracic ultrasound (involving imperceptible
high frequency vibrations above 20 kHz) has been inves-
tigated to improve IV thrombolysis in STEMI, however
clinical trials involving this technique (PLUS Trial [6]),
have thus far failed to show efficacy, probably due to the
problematic high attenuation characteristics of ultra-
sound through a relatively thick chest wall and lung [7],
with thereby an apparent need for advanced skill based
imaging techniques to direct the therapy [8]. Ultrasound
further harbors a propensity, especially at higher inten-
sities, to lead to increased platelet adhesion [9], damage
blood vessels [10-15] and burn the overlying skin of
patients receiving therapy [13,14].
Our group has been working on the premise that in-
frasonic to sonic Low Frequency Vibro-Percussion (LFVP)
(a waveform with a much higher, palpable stroke ampli-
tude than ultrasound), may offer a safe, effective acous-
tic alternative in the non-invasive treatment of STEMI
due to LFVP’s known clot disruptive abilities [16-20],
superior deep penetration capabilities across the chest
wall [21,22] and unique internal transmission character-
istics through body tissue including arteries and the
epi-myocardium [23-26]. However study of this area
has been scarce, and there has yet to be even basic in-
vitro verification that LFVP if engaged over a substan-
tial tissue attenuation barrier (i.e. sized comparably to a
human chest wall) would actually penetrate to provide
agitative thrombo-clearing effects to an underlying clot-
ted, coronary like vessel. We have previously reported on
LFVP’s ability to clear thrombosis in a coronary like flow
tube when applied over a 2 cm thick meat barrier [20],
but have been criticized that the chest wall is considerably
thicker than 2 cm, and that we did not test LFVP’s effects
in combination with its preferred medical adjunct - a
thrombolytic agent.
Hence we periodically engaged a 50 Hz, ~4 mm per-
cussive massager against a 4 cm thick meat barrier di-
rectly overlying a clot filled, Heparinized, coronary
like tube system to assess whether LFVP would pene-
trate and enhance clot dissolution and/or any other
clot disruptive effects within the tube. We then
repeated the trial with a co-administration of Strepto-
kinase (SK) administered remotely ~ 2.0 cm upstream
from the clot.
Methods
Work developing our experiment was performed in a
private lab setting (In-Vitro Labs, Burnaby, B.C.,
Canada). The test subjects (the Authors, a healthy male
and female), who donated blood gave consent to the
study which had been approved by Institutional Review
[27] in accordance to the U.S. Department of Health &
Human Services Basic Policy for Protection of Human
Research Subjects.
Vibrating equipment
We chose a hand-held massager (Acuvibe HT 1280)
which oscillates at 50 Hz with a percussive stroke ampli-
tude of ~4 mm as judged by the width of the contact
node’s corona during active vibration. This provided for
a moderate intensity vibration which we have shown in
our lab to be tolerable when applied to the ribcages of
both men and women.
A percussive frequency of 50 Hz was chosen as it has
been shown that externally delivered diastolic timed
LFVP (“dLFVP”) at 50 Hz enhances cardiac performance
[21,28,29] as well as coronary flow, both in animals and
humans, in the ischemic heart [30-32]. Furthermore,
50 Hz is also within the range of frequencies used in vi-
brating thrombolysis catheters such as the TrellisW 8 Pe-
ripheral Infusion System (Bacchus Medical) which uses
motor speeds up to 3500 rpm which causes direct me-
chanical oscillation of the catheter’s wire [16]. Moreover
50 Hz is in the range of frequencies shown to induce trans-
verse wave propagation along the heart’s epi-myocardium
and along the length of arteries, [23-26], hence once
applied – and unlike ultrasound - should provide an
optimized internalized propogative effect to the enti-
rety of a coronary circulation regardless of overlying
acoustic attenuating structures and without a need for
skill based targeting of the therapy. Additionally, LFVP
including at 50 Hz produces convection currents and
vortices in fluids [33,34], which we have observed first
hand to be highly desirable in effecting erosion and
mixing of blood clot constituents. Finally, to our
knowledge there has been no reported evidence of
harmful effects of infrasonic to sonic frequency vibra-
tion (i.e. for short term therapeutic exposures) in tissue
heating or on blood vessels [Medline review, 2012].
It is again emphasized that this trial does not involve
the employment of ultrasound, but rather a much lower
frequency and higher amplitude, palpable, vibratory -
percussive waveform in the low sonic frequency ranges.
“Diastolic” timing
As an emergency transthoracic LFVP for STEMI appli-
cation would foresee ably be timed to turn “on” during
diastole and “off” during systole (i.e. “dLFVP”), we mim-
icked this condition by engaging and then very briefly
disengaging our massager at one second intervals timed
by a metronome. The administration of pulsated pres-
sure was coordinated by a second investigator such that
the “diastolic” (lower phase) of the pulsated waveform
matched delivery of LFVP.




As a clot/fluid interface we chose pressurized Hepari-
nized Saline (HS-1000 Units/500 ml bag in 0.9% NACL
@~pulsated ~ 120/80 mm HG, ~ 60 bpm), to ensure
clot constituents would not reform once disaggregated,
and to provide a small degree of anticoagulant drug type
therapy (with pulsatile arterial like filtration-pressure) to
closer mimic an anticipated emergency clinical scenario.
HS plus Streptokinase (SK)
As an adjunctive thrombolytic agent we chose Strepto-
kinase (75,000 IU ~ 15,000 IU/100 microlitre, 0.5 ml
bolus) administered to the proximal end of our throm-
bosed catheter segment in compliment to the adjoining
distal aspect of our connecting line which equated to an
interfacing edge SK location (depending on clot length)
of approximately 1.5 to 2.5 cm (usually ~ 2.0 cm) up-
stream from the clot. Remote SK delivery was employed
to mimic an intravenous (or systemic) delivered dose of
thrombolytic which would initially be of negligible con-
centration in direct proximity to an acute thrombosis
site within a culprit artery. As a stock solution to a com-
mercially available lyophilized SK vial (750,000 I.U.) 5 ml
of sterile water was added and mixed to yield a concen-
tration of 15,000 IU/100 microlitrea. The stock solution
was kept refrigerated at 4 degrees Celsius when not in
use (for repeat testing on following days), and was al-
ways discarded and replenished after 5 days following
reconstitution.
Harvesting and treatment of clots
The experiment was performed via the assistance of two
blood donors (the Authors – male 46 yrs, female 50 yrs),
neither having evidence of blood coagulation disordersb
or acute illness, and without a recent history of oral
contraceptive use and never anticoagulant therapy.
For each sample run an aliquot of blood was drawn to
fill a red top vacucontainer which was then held upright
within the armpit of an investigator for 1 hour to main-
tain core temperature. This produced a long columnar
“mother” clot which was laid upon a dry plastic sheet
and immediately roll dried for 20 cm, allowed to air dry
for 5 minutes, and then further roll dried for another
20 cm to rid the clot of gross amounts of adherent
serum. We then cut a ~ 0.75 cm piece of “daughter” clot
lengthwise, roll dried it for 30 cm, air dried for one mi-
nute, and then role dried again for an additional 30 cm.
The daughter clot (now “dry” enough of adherent serum
to handle) was then corralled into the open end of a 3
ml syringe, where after a pre-weighted segment of Soft
Flo catheter (with a 4 mm lumen diameter – a size con-
sistent with a large epicardial coronary artery) was
uncapped distally to receive the clot by needleless
injection. Once loaded the catheter segment was tilted
with the uncapped distal end facing downwards to allow
gravity to migrate the delivered clot flush against the
distal cap during re-securement. The capped catheter
segment was then wiped and re-weighted to obtain a
pre-clot weight. Blood clots were manipulated in this
manner for each test run.
Establishment of vibration system
At the beginning of each testing period an HS solution
bag spiked with a regular connecting line was placed in
a pressure sleeve and hung. Prior to each test run HS
was slowly injected into the uncapped proximal aspect
of the catheter segment to fill its lumen while not intro-
ducing air or significantly agitating the clot within. We
then forcefully secured the open blue tipped proximal
end of the catheter segment (drop to drop, to yield a
fluid connection) with the connecting line. The catheter
segment (now with connecting line) was then secured
with tape (Transpore, 3M) upon a curved gel pad wrist
support (Fellows Inc.), and the HS bag was pressurized
to ~80 mm Hg. We then photographed the system to
document the clot’s initial condition and how much fluid/
clot boundary mixing of dissolved clot constituents had
initially taken place (a grade of 0 was given if there was in-
complete catheter filling of partially transparent, red color
in the lengthwise dimension, a grade of 1 if there was
complete catheter filling of red color only in the length-
wise dimension but not at any point in the height wise di-
mension, a grade of 2 being same as 1 but if any red color
had migrated beyond the blue tipped connector of the
catheter segment into the connecting line, a grade of 3 if
color was at any point fully red within the catheter in its
height dimension, a grade of 4 if the catheter became
completely red - height and length - with up to 2 cm of
color having permeated into the connecting line, a grade
of 5 being the same as 4 but between 2 cm and 20 cm of
red color having permeated proximally into the connec-
ting line, a grade of 6 being same as 5 but with red color
having permeated beyond 20 cm and up to 30 cm up into
the connecting line, and finally a grade of 7 was given
being the same as 6 but with red color having permeated
beyond 30 cm up into the connecting line).
A 4 cm thick slab of Salami meat (thickness resem-
bling a typical distance from human chest wall to anter-
ior surface of the heart [Author’s experience in
Echocardiography]), was then placed over the clotted
catheter system. The slab was covered with its original
plastic wrapping and re-enforced with tape (again Trans-
pore 3M) so its shape would hold during forceful LFVP
application. The slab was then randomized to receive
intermittent (engaged and very briefly disengaged at one
second intervals) 50 Hz, ~4.0 mm LFVP, vs. no LFVP
for 20 minutes. HS (in pressure sleeve) was manually
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pulsated from ~80 mm Hg to ~120 mm Hg at a rate co-
ordinated such that the “diastolic” phase of the arterial
like pulsations matched intermittent LFVP delivery. A
second experimenter (pulsating the HS bag) was kept
blinded to whether the vibration was actually applied to
the clotted system or to a sham meat patty. LFVP
transmission from slab to catheter was at all times
visually verified by an obvious vibratory response of
the connecting line which projected from underneath
the slab (See Figure 1).
Periodic small breaks (a dozen or so seconds cessation
of LFVP engagement) were taken every 5 minutes dur-
ing the 20 minute treatment period so the investigator
could briefly inspect the integrity of the catheter system,
rest his hand, and document for any changes to the clot-
ted system.
After 20 minutes of LFVP (vs. no LFVP) the meat slab
was removed and connecting line was fully constricted.
We then photographed the system to document for
signs of clot disruption (i.e. clot morphology, fluid chan-
nel development along the sides or within the clot, clot
mobilization, clot fragmentation, and degree of dissolved
clot constituent mixing as seen as a red color having
migrated within the catheter segment and if applicable
up the connecting line). The catheter segment was then
disconnected from the connecting line and aspirated of
visibly accessible fluid via an 18 GA, 6.00 in BD spinal
needle. To prevent accidental clot removal care was
taken to keep the beveled opening of the needle against
the catheter wall during aspirations, and aspirations
were only attempted beyond a leading edge of a clot
when there was a clear indentation or equivalent access-
ible fluid pathway to allow access without significantly
disturbing the clot. In rare cases when the clot migrated
proximally within the catheter segment the distal cap
was first unplugged and forward flow was slowly permit-
ted from the connecting line to bring the clot back to its
original resting position, where-after the distal cap was
re-secured and the catheter segment was aspirated of
remaining fluid per normal. The catheter was then
detached from the curved gel pad and if necessary aspi-
rated again for any further accessible fluid which may
have (after handling) permeated accessibly to the clot’s
surface. An investigator then held the catheter segment
proximal blue tipped end upright for 2 minutes follow-
ing which (if any additional accessible fluid was seen) a
third and final aspiration was performed. The catheter
segment was then wiped (with particular attention to
any tape residue) and re-weighted to establish final clot
weight. Aspirations and post weighting were provided by
the second investigator (who was blinded to the type of
treatment each clot had received). Percent % dissolution
of thrombus was derived as (pre clot weight – post clot
weight)/pre clot weight × 100%.
In a second set of sample runs we repeated the experi-
ment whereby a 0.5 ml bolus of SK (15,000 IU/100
microlitre) was delivered to fill the proximal, blue tipped
end of our catheter segment in compliment with the
adjoining distal aspect of our connecting line. This equa-
ted, depending on clot size, to about a 1.5 to 2.5 cm
(most commonly ~ 2.0 cm) leading edge upstream deliv-
ery of SK with respect to the leading (interfacing) edge
of the clot. Remote SK administration was intended to
mimic an intravenous, systemic delivery scenario (typical
of pre-hospital thrombolysis applications in STEMI)
where an initial concentration of SK in direct proximity
to a culprit thrombosis would of course be negligible.
Measured parameters and statistics
Five clot disruptive parameters were noted in this
experiment
1) Percent Clot Dissolution (for assessment of LFVP”s
ability to de-bulk clot, with or without a
thrombolytic agent). Percent Clot Dissolution was
calculated as (pre clot weight – post clot weight)/pre
clot weight × 100%.
2) Dissolved clot constituent mixing within the catheter
segment and if applicable up the connecting line
Figure 1 Our vibration set up. A 50 Hz massager was
intermittently engaged upon a 4 cm thick meat slab overlying our
clotted catheter segment. Visible is the pressurized connecting line
protruding from underneath the slab. Not seen (under the slab) is
the capped, 4 mm lumen Soft Flo Catheter segment with indwelling
clot. To view the application in real time, please refer to the
following internet link: http://www.youtube.com/watch?
v=6CIcDttuERA.
Hoffmann and Gill Thrombosis Journal 2012, 10:23 Page 4 of 16
http://www.thrombosisjournal.com/content/10/1/23
(to confirm clot dissolution, and for assessment of
LFVP’s ability to provide upstream fluid turbidity to
assist clot erosion and provide a facilitated diffusive
mechanism for enhanced drug delivery). A “Relative
Mixing Score” (+0 to +7) was calculated for each
sample as the difference between the initial and
maximum observed mixing scores during the
treatment period.
3) Development of clot length intra-luminal fluid
channels, including documentation of speed of
channel development (for assessment of LFVP’s
ability to induce morphologic changes in a clot
within a vessel lumen consistent with an expectation
for early reflow).
4) Clot mobilization, (for assessment of LFVP’s
propensity to generally destabilize and clear a clot
from its original resting position), and
5) Clot fragmentation (for assessment of LFVP’s
propensity to generally disrupt or break apart clot).
Values for Percent Clot Dissolution and Relative Mixing
Score (LFVP samples vs. controls) were computed for
their Means +/− Standard Deviation, and then compared
for statistical difference by the Student’s 2 – tailed T test.
Values for development of; clot length fluid channels,
clot mobilization and clot fragmentation (LFVP samples
vs. controls) were reported as “Yes” or “No” and then
computed to a percentage and compared for statistical
difference by the Fisher’s 2 – tailed exact test.
Time to first observation of clot length channel develop-
ment was reported in minutes (i.e. 5, 10, 15 or 20 minutes).
P values of less than or equal to 0.05 were considered
statistically significant.
Results
Pulsated HS only (without SK)
Percent clot dissolution
LFVP samples demonstrated a minor but consistent en-
hancement of Percent Clot Dissolution vs. controls with
23.0% +/− 5.0% vs. 1.8% +/− 1.2% respectively (p < 8.5 E - 6).
Dissolved clot constituent mixing
LFVP samples demonstrated statistically superior Rela-
tive Mixing Scores vs. controls with values of 5.0 +/− 0.5
vs. 0.8 +/− 0.5 respectively (p < 2.8 E −6). Dissolved red
blood constituents fully diffused within the catheter seg-
ment and often migrated well up into the connecting
line in the LFVP group, whereas this phenomenon (to
this degree) was completely absent in the control group.
Development of clot length fluid channels
LFVP samples showed a strong superiority in develop-
ment of clot length fluid channels (notably at the clot’s
edges) versus the controls, with the effect exclusively
occurring in the LFVP group (8/8 vs. 0/8 respectively,
p < 0.0002).
Development of clot length fluid channels were
observed to occur relatively late in the course of treat-
ment, usually within the last 5 to 10 minutes of the total
20 minute LFVP period.
Clot mobilization and fragmentation
LFVP samples occasionally demonstrated clot mobili-
zation (2/8) and rarely clot fragmentation (1/8) which
again occurred exclusively in the LFVP group. These
results however did not statistically differ in com-
parison with the control group (p < 0.5 and p = 1.0
respectively).
Results are shown below in tabular form (see Tables 1,
2, 3, and 4).
Typical pre and post treatment conditions of control
versus LFVP treated clots are shown in Figures 2, and 3
respectively. A typical degree of post treatment dissolved
clot constituent mixing having permeated into the con-
necting line of a control vs. LFVP sample is shown in
Figure 4. Typical post treatment conditions of a pair of
control vs. LFVP clots (following expiration from the
catheter segment) are shown in Figure 5. Photograph’s in
documentation of the LFVP run which showed clot
mobilization and fragmentation (regarding sample no. 8)
are depicted in Figure 6.
Pulsated HS with remotely administered SK
Percent clot dissolution
SK enriched LFVP samples demonstrated a marked, signifi-
cant enhancement of Percent Clot Dissolution in compa-
rison to controls with 51.0% +/− 4.6% vs. 3.0% +/− 1.5%
(p < 9.8 E – 6).
The mean difference improvement in Percent Clot
Dissolution in the SK enriched LFVP group (48%) versus
the SK non-enriched, HS only LFVP group (21%) was
more than double.
Dissolved clot constituent mixing
SK enriched LFVP samples continued to demonstrate
statistically superior Relative Mixing Scores vs. controls
with values of 5.1 +/− 0.6 vs. 0.9 +/− 0.4 respectively
(p < 2.8 E-6).
SK enriched LFVP samples usually demonstrated a
high degree of clot constituent mixing (i.e. up into the
connecting line) relatively early during LFVP therapy,
but then later during treatment the red color indicator
would often dissipate within the connecting line such
that it was no longer (or just barely - faintly) evident. In
these cases the maximum degree of observed mixing
over the course of therapy was taken for statistical
purposes.
Hoffmann and Gill Thrombosis Journal 2012, 10:23 Page 5 of 16
http://www.thrombosisjournal.com/content/10/1/23
Development of clot length fluid channels
SK enriched LFVP samples continued to show a strong
statistically significant superiority in development of clot
length fluid channels versus the controls (8/8 vs. 0/8 re-
spectively p < 0.0002).
Development of clot length fluid channels were
observed to occur relatively early in the course of SK
enriched LFVP treatment (i.e. in comparison to the HS
only LFVP groups), usually within the first 5 to 10 min-
utes of the total 20 minute treatment period.
Clot mobilization and fragmentation
SK enriched control samples never demonstrated clot
mobilization or fragmentation. LFVP samples with SK
demonstrated clot mobilization once (1/8), and never
fragmented (0/8). The differences between the test
groups were not statistically significant (p = 1.0 in both
cases).
Results are shown below in tabular form (see Tables 5,
6, 7, 8 below).
Typical pre and post treatment conditions of clots
exposed to pulsated HS with remotely administered SK
without and with “diastolic” timed LFVP are shown in
Figures 7 and 8 respectively. The degree of dissolved clot
constituents permeating up into the connecting line of a
typical SK enriched control versus LFVP sample is
shown in Figure 9. The post treatment condition of a
pair of SK enriched control vs. LFVP treated clots
(following expiration from the catheter segment) are
shown in Figure 10. Photographs in documentation of the
SK enriched LFVP run which caused clot mobilization
(regarding sample no. 9) are shown in Figure 11.
Discussion
This experiment confirms that LFVP (50 Hz, ~4.0 mm),
periodically applied during the diastolic phase of a series
of arterial like pressure pulses and engaged upon a 4 cm
meat barrier provides enhanced clot disruptive effects in
an underlying coronary like tube system. This is a first
demonstration that LFVP engaged across a chest wall
sized barrier can penetrate to yield potential thrombo-
Table 2 Mean percent clot dissolution +/− standard
deviation of samples when treated by pulsated HS and
LFVP (LFVP), vs. no LFVP (Control)
Group #Samples % Clot dissolution
(mean +/− standard
deviation)
LFVP 8 23.0% +/− 5.0%
Control 8 1.8% +/− 1.2%
The differences were statistically significant (p < 8.5 E - 6).
Table 3 Percentage development of clot length fluid
channels of samples when treated by pulsated HS and
LFVP (LFVP), vs. no LFVP (Control)




The differences were statistically significant (p < 0.0002).
Table 1 Summary of results (HS only group)
No. Donor Treatment Pre-Wt. Post Wt. (%) R.M.S. Channels (min) Mobilized Fragmented
1 HG Control 0.357 0.353 1 +1 No - No No
2 AH Control 0.346 0.333 4 +0 No - No No
3 HG Control 0.360 0.353 2 +1 No - No No
4 AH Control 0.330 0.327 1 +1 No - No No
5 HG Vibrate 0.287 0.231 20 +5 Yes 15 Yes No
6 AH Vibrate 0.229 0.188 18 +5 Yes 20 No No
7 AH Control 0.280 0.282 0 +1 No - No No
8 HG Vibrate 0.279 0.190 32 +5 Yes 10 Yes Yes
9 HG Control 0.377 0.371 2 +1 No - No No
10 AH Vibrate 0.423 0.310 27 +5 Yes 20 No No
11 AH Control 0.290 0.285 2 +1 No - No No
12 HG Vibrate 0.331 0.268 19 +5 Yes 15 No No
13 AH Vibrate 0.267 0.214 20 +4 Yes 20 No No
14 HG Vibrate 0.311 0.246 21 +5 Yes 20 No No
15 AH Control 0.299 0.294 2 +0 No - No No
16 HG Vibrate 0.323 0.236 27 +6 Yes 20 No No
Results of Percent Clot Dissolution (%), Relative Mixing Score (+ 0 to +7), clot length fluid channel development (Yes or No), time by which clot length fluid
channels were first observed (min), clot mobilization (Yes or No) and clot fragmentation (Yes or No) in view of a 20 minute exposure of pulsated HS coordinated
with “diastolic” timed LFVP (“Vibrate”) versus pulsated HS alone (“Control”). Donors, AH = Andrew Hoffmann (male), HG=Harjit Gill (female).
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clearing effects, with the effects accentuated in conjunc-
tion with a remotely delivered thrombolytic agent.
The first notable finding in our experiment was an ob-
vious development of clot length fluid channels in all
LFVP samples (i.e. SK enriched and non-enriched)
which were completely absent in all control samples.
Such channeling alongside or within a clot would cer-
tainly predict a therapeutic benefit as early reflow along
with enhanced penetration of systemically delivered
therapeutic drug agents would undoubtedly be pro-
moted. As LFVP is known to produce convective cur-
rents [33,34], it is probable that LFVP induced shear
forces within the HS (+/− SK) solution likely acted upon
(or eroded) the loosely aggregated platelet surface along
the young clot’s edges. It is also possible that vibro-
agitation with accompanying catheter wall deformations
may have added to the erosive effect, and at least partly
caused the clot to unfurl, or lay more extended lengthwise
along the catheter’s lumen (which was a general observa-
tion noted in our experiment). Channel development gen-
erally occurred faster and more extensively in the SK
enriched vs. non-enriched group.
A second notable finding was that while we observed
a consistent but somewhat “under-whelming” improve-
ment in Percent Clot Dissolution in the non-SK
enriched LFVP group versus control (i.e. 21% - which
might be to slight a change to predict a clinical benefit),
we however more than doubled this improvement (to
48%) in the SK enriched group. The improved effective-
ness of LFVP with remotely administered SK (a pairing
which we have dubbed “Vibrinolytic Therapy”) is likely
explained by a combination of introduced proximal fluid
turbulent mixing (as a means for enhanced thrombolytic
delivery - discussed more thoroughly below), along with
the above mentioned development of clot length fluid
channels which would enhance clot surface area expos-
ure and fibrin binding sites to the penetrating SK
molecule.
A third notable finding was an observed marked en-
hancement of dissolved clot constituent mixing in the
LFVP samples (as evidenced by the diffusive permeation
of partially transparent red color within the full height of
the catheter segment and up into the connecting line),
which was substantially unobserved in the control sam-
ples. This finding, besides confirming that significant clot
dissolution had taken place, supports our suspicions that
LFVP may have promoted delivery of SK towards the clot
interface by a turbulent mixing phenomenon. Indeed, the
relatively slow mass transport of systemically introduced
clot busters down occluded thrombosed arteries and
into clots (where the process is by in large dictated by
arterial based filtration pressure with non-facilitated dif-
fusion [35]) has certainly been an Achilles Heel in the
mechanistic effectiveness of conventional, passively intro-
duced IV thrombolytic therapy. Clearly that remotely
delivered SK in our experiment was shown to be negligibly
effective in clot dissolution without LFVP and note-ably
effective with LFVP supports the view that a degree of
enhanced drug transport had most probably taken place.
That LFVP enhances mixing between two adjacent
fluids is supported in fluid mechanics. It has been solidly
established that mix ability of solutes and parallel fluids
within an agitated fluid system is several orders of mag-
nitude greater than what is seen in laminar (and espe-
cially absent) flow, due to the introduced random
velocity and density gradients which cause eddies and
vortices which greatly accelerate diffusion and mass
transport [36,37]. Indeed the correlation of increased
mass transfer co-efficient between two fluids given an
added LFVP application has been experimentally verified
by Hancil et al. [38]. Further, Oberti et al., have shown
enhanced mixing of particulate laden fluids in articulat-
ing channels (analogous to articulating blood vessels)
secondary to external LFVP [39,40]. Accordingly, LFVP
mixing devices such as produced by Resodyn™ Acoustic
Mixers (operable at a nominal frequency of 60 Hz) have
Table 4 Mean relative mixing scores +/− standard
deviation of samples when treated by pulsated HS and
LFVP (LFVP), vs. no LFVP (Control)
Group #Samples Relative mixing score
(mean +/− standard deviation)
LFVP 8 5.0 +/− 0.5
Control 8 0.8 +/− 0.5
The difference was statistically significant (p < 2.8 E −6).
Figure 2 Pre and post control sample (HS only group). Image (left) depicts the pre-condition of a typical control sample (from sample no. 9).
Image (right) depicts the sample following 20 minutes of pulsated HS only, showing only minor changes.
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found common use in industrial mixing of both fluids
and solids.
A fourth notable finding in our experiment was that
clot mobilization within the catheter segment was quite
rare, and when occurring was also only observed in an
LFVP group. While the mechanism for this is specula-
tive, it is likely that the transmitted vibration simply
caused disadhearment (or detachment) of the clot
from along the catheter walls and the distal cap,
which thereby allowed the clot to move freely within
the agitated solution. There was no statistical differ-
ence in the likelihood of mobilization between SK
enriched (1/8) and non-enriched (2/8) LFVP treat-
ment groups.
A final notable finding to our experiment was that clot
fragmentation (with division of clot into separated
pieces) was also very rare, occurring only once in a SK
non-enriched LFVP “HS only” group. Again while the
mechanism for this is also speculative, it is likely that
clot fragmentation may be simply a result of more ex-
tensive clot erosion with possibly an increased surface
tension along the clot’s length during vibration induced
lengthening and de-furlment. Inspection of LFVP treated
clots (although more commonly in the SK enriched sam-
ples) did show aspects of extreme clot thinning into tiny
strands – which amazingly were able to keep the clot in-
tact. It is worth mentioning how strong these tiny
strands (which are often as thin as a strand of spider’s
Figure 3 Pre and post LFVP treated samples (HS only group). Images (left) depict the pre-condition of three typical LFVP samples (top to
bottom, from sample no.’s 6, 10 and 16 respectively). Images (right) depict the samples following 20 minutes of pulsated HS coordinated with
“diastolic” timed LFVP. Note the development of clot length fluid channels and extensive mixing of red colored dissolved clot constituents within
the catheter segment.
Figure 4 Post treatment clot constituent mixing (Control vs. LFVP sample). Image (left) shows the typical (and absent) degree of post
treatment dissolved clot constituent mixing into the connecting line of a control sample (from sample no. 9). Control samples never at any time
showed any permeation of red color into the connecting line. Image (right) shows the comparatively pronounced degree of mixing commonly
observed in a LFVP sample (image taken from sample no. 10).
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web!) can be, being able to support the majority weight
of the remainder of a clot when being held upright by
the hand of an investigator (refer to Figure 10).
Our findings raise the interesting question whether
chest wall delivered LFVP in the low sonic frequency
ranges (as opposed to, or maybe even working co-
operatively with therapeutic ultrasound?) may hold
potential as a knock out “one–two punch” in aid of clot
disruptive, and more particularly IV thrombolytic ther-
apy in treatment of STEMI. First by mechanically erod-
ing clot surface layer and altering clot morphology to
promote intra-luminal fluid channel development (which
would enhance early flow and uncover fibrin binding
sites), and second by facilitating diffusive bulk flow of
Figure 5 Post treatment clot morphology (Control vs. LFVP samples). Images (left) show the post condition of a pair of control clots
following treatment (top to bottom from sample no. 11 and 9 respectively). Images (right) show the post condition of a pair of LFVP treated clots
(top to bottom from sample no. 16 and 10 respectively). Note the smooth surface of the control clots in comparison to the more jagged, eroded
appearance of the vibrated clots.
Figure 6 Images from LFVP sample no. 8 which led to clot fragmentation. Image (upper left) depicts the clot’s pre-condition (mixing score
graded 0). Image (upper right) depicts the catheter segment following 20 minutes of “diastolic” timed LFVP (in this sample the clot migrated
proximally from the catheter’s distal cap). Image (middle left) shows dissolved clot constituent mixing, including part of the clot, which had
migrated up the connecting line (mixing score graded 5, Relative Mixing Score therefore +5). Image (middle right) shows the clot after being
flowed back to its original position. Image (bottom) shows a sample of the expired clot which had fragmented.
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clot disruptive drug agents from a concentration rich
systemic circulation towards a concentration poor,
otherwise stagnant, thrombosed coronary vessel.
It should be pointed out that transthoracic LFVP is
prophesized to promote early clearance of acute coron-
ary thrombosis by numerous additional mechanisms,
which are beyond the scope of our present study.
First, it has been shown both clinically and in animal
models that dLFVP when applied to the heart im-
proves ischemic LV function, by improved myocardial
relaxation, which has been attributed to enhanced dia-
stolic filling leading to increased stroke volume by the
Frank Starling mechanism [21,28,29]. This, by stabilizing
a STEMI patient’s blood pressure (for example during
heart failure or cardiogenic shock), would also augment
systemic filtration pressures in assistance of bulk flow
permeation of clot busters into a site of culprit
thrombosis.
Second, improved myocardial relaxation by dLFVP
would theoretically decrease coronary arteriolar and ca-
pillary flow resistance (by reduced diastolic myocardial
compression) and is known to lower left ventricular (LV)
diastolic pressures [21], which in combination should as-
sist coronary flow and microcirculation during or follow-
ing reperfusion.
Third, there is good evidence that LFVP carries potent
vasodilatory capabilities for arteries in states of heigh-
tened vascular tone (i.e. by induced relaxation of the
smooth muscles in the vessel wall) [41-43], and thus
holds potential to induce direct coronary dilation at the
site of acute coronary thrombosis, which often has (in at
least 50% of STEMI cases) a degree of associated
Table 5 Summary of results (SK enriched group)
No. Donor Treatment Lytic Dist Pre-Wt. Post Wt. (%) R.M.S. Channels (min) Mobilized Fragmented
1 AH Control 2.1 cm 0.258 0.254 2 +1 No - No No
2 AH Vibrate 2.0 cm 0.297 0.184 38 +5 Yes 10 No No
3 HG Vibrate 2.0 cm 0.295 0.177 40 +5 Yes 10 No No
4 HG Control 2.1 cm 0.288 0.280 3 +1 No - No No
5 AH Vibrate 1.5 cm 0.371 0.206 44 +6 Yes 10 No No
6 AH Vibrate 2.5 cm 0.255 0.126 51 +41 Yes 5 No No
72 HG Vibrate 1.5 cm 0.352 0.161 54 +5 Yes 10 No No
8 HG Control 2.3 cm 0.262 0.246 6 +03 No - No No
9 AH Vibrate 2.5 cm 0.236 0.061 74 +6 Yes 5 Yes No
10 AH Control 1.5 cm 0.453 0.436 4 +1 No - No No
11 HG Vibrate 1.8 cm 0.303 0.125 59 +5 Yes 5 No No
12 AH Control 2.1 cm 0.286 0.280 2 +1 No - No No
13 HG Control 1.9 cm 0.299 0.290 3 +1 No - No No
14 HG Control 1.6 cm 0.341 0.338 1 +1 No - No No
15 AH Vibrate 2.3 cm 0.255 0.133 48 +5 Yes 5 No No
16 HG Control 2.3 cm 0.259 0.251 3 +1 No - No No
Results of; initial lytic to clot separation distance (cm), Percent Clot Dissolution (%), Relative Mixing Score (+0 - +7), clot length fluid channel development (Yes or
No), time to first observation of clot length fluid channels (min), clot mobilization (Yes or No) and clot fragmentation (Yes vs. No), in view of a 20 minute exposure
of remotely administered SK in conjunction with “diastolic” timed LFVP (Vibrate) vs. no LFVP (Control). Donors, AH = Andrew Hoffmann (male), HG=Harjit Gill
(female).
1Diminished mixing score in this sample was likely attributed to the relatively small initial clot size (with a leading edge ~2.5 cm from SK).
2This sample run developed a significant leak between the connecting line and blue tip connector of the catheter segment which could not be corrected. Only
about 10 minutes of effective LFVP therapy was administered. Mixing score was based on maximum observed prior to the leak.
3Relatively low mixing score in this sample may have also been attributed to a relatively small clot size (with leading edge 2.3 cm from SK).
Table 6 Mean percent clot dissolution +/− standard
deviation of samples when treated by pulsated HS-SK
and LFVP (LFVP - SK), vs. no LFVP (Control - SK)
Group #Samples % clot dissolution
(mean +/− standard deviation)
LFVP – SK 8 51.0 % +/− 4.6%
Control – SK 8 3.0 % +/− 1.5%
The differences were statistically significant (p < 9.8 E −6).
Table 7 Percentage development of clot length fluid
channels of samples when treated by pulsated HS-SK and
LFVP (LFVP - SK), vs. no LFVP (Control - SK)
Group #Samples Development of clot
length fluid channels
LFVP - SK 8 100%
Control - SK 8 0%
The differences are statistically significant (p < 0.0002).
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localized coronary spasm [44-47]. It is also worth men-
tioning that cyclic stress and strain exerted on an endo-
thelial lining of an artery (which would likely be induced
through a prophesized LFVP application)c, is predictive
to cause liberation of beneficial mediators such as Nitric
Oxide (NO) which is also a potent vasodilator [48]. In-
deed low frequency vibration stimuli has been experi-
mentally shown to trigger NO release in various tissues
[49-51]. LFVP’s vasodilatory mechanism in particular
may therefore offer a degree of near immediate early re-
flow in a high percentage of STEMI victims.
Fourth, LFVP should encourage disadhearement of
acute thrombosis from the coronary wall (i.e. from site
of ruptured plaque), and thereby promote very early
recanlization of the major culprit epicardial vessel. Ex-
ternal LFVP’s ability to clear clot from a stenosis site has
been shown previously by our group [20], and has also
been demonstrated by Folts et al. in reliable and imme-
diate clearance of acute coronary and carotid thrombosis
(albeit at a lower frequency, via direct hand tapping or
shaking of the acutely thrombosed vessel) in open ani-
mal models [19].
Fifth, LFVP is known to stimulate endogenous liber-
ation of fibrinolytic mediators [52,53], thereby poten-
tially offering a natural augmentation for localized
fibrinolyis.
Six, LVFP should curtail stagnant arteriolar/capillary
flow by prophylactic agitation of distal clotted fragments
and by possibly lowering blood viscosity [54,55], which
may further assist in microcirculation during or follow-
ing reperfusion. Researchers at Mt. Sinai Medical Centre
(Miami, Florida) have recently studied the effects of low
sonic vibration applied to the chest wall of rats which
showed an up-regulation of endothelial derived NO
Synthase (eNOS) with enhanced NO release, which in
addition to its therapeutic vasodilatory properties has
been discussed as a potential cardio protective mechan-
ism in limitation of ischemic reperfusion injury [56].
There were several limitations to this present study.
Firstly, the degree of removal of accessible fluid by our
aspiration weighting technique could not be made iden-
tical between test runs. Great care however was taken to
remove fluid using the same technique and in near iden-
tical fashion between samples, and the individual provid-
ing the post weighting was kept blinded to the form of
treatment the clot was to, or had received. Secondly the
meat slab was only a crude approximation of an overly-
ing chest wall (lacking muscle fibers, ligaments, fat, fi-
brous pericardium, pericardial fluid and lung), and the
underlying clotted vessel comprised a flexible catheter
segment rather than a live coronary artery. However we
felt that as an early experiment to assess LFVP’s ability
to transmit and provide a basic clot disruptive effect
over a thick chest wall sized attenuation barrier, this
would at least provide a good “go–no go” hypothesis in
that if LFVP produced a negligible effect the application
would most certainly fail under less ideal clinical cir-
cumstances. It should be mentioned that LFVP has been
shown to penetrate effectively from the human chest
wall to the heart (even causing vibratory deformations to
the deep posterior wall) by Koiwa and his associates by
use of a more gentle vibration device (2 mm amplitude)
than what we used in our experiment [21,31]. Thirdly
we had the advantage of localizing the vibrator place-
ment upon the meat slab to ensure that the catheter seg-
ment underneath was vibrating, whereby this advantage
would be absent clinically. However, the design of a vi-
bratory attachment interface specific for inter-ribspace
chest wall applications is presently underway which
enables enough coverage over the base of the heart to
maximize the chances that an LFVP source would gen-
erally overly a culprit coronary vessel [57]. Fourthly, we
cannot say by direct observation whether the relative
improvement of remotely administered SK effectiveness
with LFVP was due to a process of enhanced drug deliv-
ery (by facilitated diffusion), or simply an enhanced loca-
lized interaction of thrombolytic agent at the clot
Table 8 Mean relative mixing scores +/− standard
deviation of samples when treated by pulsated HS - SK
and LFVP (LFVP - SK), vs. no LFVP (Control - SK)
Group #Samples Relative mixing score
(mean +/− standard deviation)
LFVP - SK 8 5.1 +/− 0.6
Control - SK 8 0.9 +/− 0.4
The difference was statistically significant (p < 2.8 E −6).
Figure 7 Pre and post control sample (SK enriched group). Image (left) depicts the pre-condition of a typical SK enriched control sample
(from sample no. 1). Image (right) depicts the sample following 20 minutes of pulsated fluid only showing only minor changes.
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interface. The minimal degree of SK clot dissolution
without LFVP however (virtually absent, only 3%)
strongly suggests that the controls had very little if any
contact with the SK molecule, so there very likely was at
least a degree of enhanced drug delivery in the LFVP
samples. Finally this study, because it was not a “flow
model”, provided little information on whether LFVP
may promote macro-embolization of clotted fragments
downstream (or more worrisome upstream, especially in
view of LFVP enhanced turbidity) which has been a con-
cern to some colleagues. We can say however that while
the remnant clots following LFVP treatment had always
become thin and eroded in appearance, in only one rare
occurrence (in 1 of 16 samples) was actual clot fragmen-
tation observed (see Figure 6). Hence the chances of a
macro-embolic proximally situated piece of clot breaking
off and flying out towards the systemic circulation would
seem, at least from our study, unlikely. Clot fragments of
course by common wisdom would generally tend to
mobilize (if at all) downstream along with the vessels
pressure gradient – to less harmful territory. In our ex-
periment we did see LFVP promoted red color (repre-
senting dissolved, disaggregated, clot constituents)
moving upstream towards and into the connecting line,
Figure 8 Pre and post LFVP treated samples (SK enriched group). Images (left) depict the pre-condition of three SK enriched LFVP samples
(images, top to bottom taken from sample no.’s 6, 11 and 15 respectively). Images (right) depict the samples following 20 minutes of pulsated
fluid coordinated with “diastolic” timed LFVP. Note the obvious decrease in clot size and development of substantial clot length fluid channels
within the catheter segment.
Figure 9 Post SK treated clot constituent mixing (Control vs. LFVP sample). Image (left) shows the typical (and again absent) degree of post
treatment dissolved clot constituent mixing into the connecting line in a SK enriched control sample (from sample no. 1). Image (right) shows
the comparatively pronounced mixing observed during an SK enriched LFVP application (from sample no. 15). Note the relative faintness of red
color in the LFVP SK treated sample which we attributed to a lytic induced dissipation effect.
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and occasionally (in 3 of 16) samples there was a degree
of upstream mobilization of the clot itself. However we
point out that our system would not allow for anything
but proximal clot mobilization (as distal flow was always
blocked by the catheter segment’s distal cap), so no cor-
relation can be drawn from our study whether there is
an adverse tendency for LFVP to mobilize clot’s
proximally versus more beneficially distally. Never-the-
less LFVP induced proximal fluid turbidity warrants
caution towards the potential of upstream liberation of
coronary originated thrombo-emboli, hence any in- vivo
study involving this prophesized application would re-
quire vigilant monitoring for stroke and acute peripheral
arterial occlusion during safety analysis.
Figure 10 Post SK treated clot morphology (Control vs. LFVP samples). Images (left) show the post condition of a pair of SK enriched
control clots following 20 minutes of pulsated fluid only (top to bottom from sample no. 4 and 1 respectively). Images (right) show the post
condition of a pair of SK enriched LFVP treated clots (top to bottom from sample no. 7 and 11 respectively). Note the relatively smooth surface of
the control clots in comparison to the much more eroded appearance of the vibrated clots which are held intact by tiny strands.
Figure 11 Images of SK enriched LFVP treated sample no. 9 yielding clot mobilization. Image (upper left) depicts the clot’s pre-condition
with SK administered 2.5 cm from the clot interface (mixing score graded 0). Image (upper right) depicts the catheter segment following 20
minutes of “diastolic” timed LFVP. In this sample the clot migrated proximally and is hidden within the catheter’s blue connecting tip. Image
(middle left) shows dissolved clot constituent mixing up into the connecting line (mixing score graded 6, Relative Mixing Score therefore +6).
Image (middle right) shows the clot after being flowed back to its original position. Image (bottom) shows the collected clot sample which had
not fragmented.
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It is worth additional historical comment that our
group has been placing faith in animal and human data
from Koiwa and his associates (studies almost two dec-
ades old!) as gospel that dLFVP when applied to a
human chest wall surface is sufficiently penetrative and
causes enhanced Left Ventricular (LV) function and cor-
onary flow in the ischemic heart. Koiwa’s work was
abandoned in or about 1996, perhaps because of lack of
funding, or because they were targeting use of their vi-
bration device for treatment of heart failure (which
probably would have been of little practical value).
Future work
The search for ideal LFVP parameters
It should be emphasized that our choice of studying
“50 Hz” (versus any other low sonic or high infrasonic
frequency) was based primarily on third party reports
(Koiwa et al’s work) which attest to the therapeutic effect
of diastolic timed 50 Hz on LV function and ability to
enhance coronary flow [28-32]. Alternatively, we have
found that 100 Hz, 0.5 mm LFVP offers clot clearing
effects across a small 2 cm meat barrier [20], and
Wobser et al. found that LFVP in the 50–500 Hz range
disrupted big blood coagula in the stomach, with better
efficacy at higher frequency levels [18]. The ability for
the heart to transmit received LFVP signals transversely
(i.e. along arteries and the epi-myocardium) has been
reported to generally occur at frequencies in the range
of 20–120 Hz [23-26], so it is conceivable that any fre-
quency within this range may comprise a reasonable
choice in causing a therapeutic agitative effect to a cor-
onary circulation. There is also the question about vibra-
tory pattern. Engineers at Simon Fraser University have
postulated that random or swept LFVP within a select
frequency range may offer superior clot disruptive
effects, such as to optimize turbulence, and ensure occa-
sional striking of an optimal resonant clot disruptive ex-
citation or cardiac frequency [58].
It is also possible that LFVP could be combined with
therapeutic ultrasound with or without co-administration
of ultrasonically active IV micro-bubbles (which oscillate
in response to ultrasound, to augment acoustic agitation
and intra-luminal sheer forces). Indeed this could be
accomplished easily by simply mounting a therapeutic
ultrasound transducer as a percussive contact (with or
without an accompanying imaging system) upon an active
end of a low frequency sonic actuator. In such an applica-
tion it could be envisioned that LFVP would provide clot
erosion and vasodilatory mechanisms to promote initial
recanalization of a TIMI 0 flow vessel, which would
thereby assist entry of systemic micro-bubbles (as well as
thrombolytic drug agents), into a thrombosed culprit cir-
culation. Much work in deciphering an optimal frequency,
vibratory pattern, and potential use of multi frequency
acoustic waveforms and adjunctive intravenous agents
remains in development of this field.
Other applications
The potential for external LFVP in the clearance of
acute arterial thrombosis is far reaching beyond coron-
ary syndromes. For example a more gentle LFVP appli-
cation (i.e. to the cranium and/or neck of a patient)
may be useful to expedite localized IV drug effectiveness
in treatment of Acute Ischemic Stroke (AIS). In fact,
Antic and his associates have demonstrated that head-
phone applied music (a gentle form of LFVP) enhances
culprit Middle Cerebral Artery (MCA) blood flow in
non thrombolysed AIS victims within a day following
admission [59]. External LFVP massage could also fore-
see ably be utilized in the acute emergency treatment of
acute pulmonary emboli (particularly in saddle emboli –
a life threatening condition) or acute peripheral arterial
thrombosis as an alternative or bridge to emergency sur-
gery or catheter based removal techniques. Clinical trials
would be required on all these fronts.
Conclusion
LFVP (50 Hz, 4 mm) timed to the diastolic phase of ar-
terial like pressure pulses and engaged upon a 4 cm
thick meat slab (analogous to a chest wall barrier, overly-
ing the heart) provides clot disruptive effects in an
underlying coronary like tube system. Percent clot dis-
solution and speed of development of clot length fluid
channels were relatively accentuated by LFVP with SK
administered ~ 2 cm upstream from the clot. Transthor-
acic, diastolic timed LFVP warrants further study in vivo
as a potential emergency treatment for STEMI.
Endnotes
aAn SK concentration of 15,000 IU in 100 microlitres
is within the range of doses shown to have good
thrombolytic effectiveness when applied in direct con-
tact to fresh clots in quiescent states in comparable in-
vitro thrombolytic testing models [60].
bBlood analysis of the Author’s showed normal values
for CBC, PT and PTT.
cAs LFVP is characterized by rapidly changing com-
pressive and expansive mechanical forces in tissue, it is
reasonable to postulate that LFVP would most likely ex-
pose the fluid and endothelial cells within the vascula-
ture to such mechanical stimuli (i.e. cyclic stress and
strain). Indeed, hydrodynamic analysis indicates that
shear stress at the wall of vessels (including the coronar-
ies) are significantly increased during bodily exposure to
low frequency vibration in the 40 to 50 Hz range [61],
hence the triggering of NO release by LFVP can there-
fore be hypothesized.
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